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Background and Purpose: Currently, there are no licensed vaccines and limited
antivirals for the treatment of COVID-19. Heparin (delivered systemically) is currently
used to treat anticoagulant anomalies in COVID-19 patients. Additionally, in the
United Kingdom, Brazil and Australia, nebulised unfractionated heparin (UFH) is
being trialled in COVID-19 patients as a potential treatment. A systematic compari-
son of the potential antiviral effect of various heparin preparations on live wild type
SARS-CoV-2, in vitro, is needed.
Experimental Approach: Seven different heparin preparations including UFH and low
MW heparins (LMWH) of porcine or bovine origin were screened for antiviral activity
against live SARS-CoV-2 (Australia/VIC01/2020) using a plaque inhibition assay with
Vero E6 cells. Interaction of heparin with spike protein RBD was studied using
differential scanning fluorimetry and the inhibition of RBD binding to human ACE2
protein using ELISA assays was examined.
Key Results: All the UFH preparations had potent antiviral effects, with IC50 values
ranging between 25 and 41 μgml−1, whereas LMWHs were less inhibitory by
150-fold (IC50 range 3.4–7.8 mgml−1). Mechanistically, we observed that heparin
binds and destabilizes the RBD protein and furthermore, we show heparin directly
inhibits the binding of RBD to the human ACE2 protein receptor.
Conclusion and Implications: This comparison of clinically relevant heparins shows
that UFH has significantly stronger SARS-CoV-2 antiviral activity compared to
LMWHs. UFH acts to directly inhibit binding of spike protein to the human ACE2
protein receptor. Overall, the data strongly support further clinical investigation of
UFH as a potential treatment for patients with COVID-19.
Abbreviations: BCA, bicinchoninic acid; COVID-19, coronavirus disease 2019; DSF, differential scanning fluorimetry; ECACC, European Collection of Authenticated Cell Cultures; hCoV, human
coronavirus; ICU, intensive care unit; LMWH, low MW heparin; NIBSC, National Institute for Biological Standards and Control; PEI, polyethyleneimine; RBD, receptor binding site; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2; SD1, spike protein subdomain 1; UFU, unfractionated heparin; VIC01, Victoria isolate 01.
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1 | INTRODUCTION
Currently, there are no licensed vaccines and limited antivirals for the
treatment of COVID-19. Repurposing existing clinical drugs with
proven safety profiles provides a rapid approach to address this gap in
treatment. Throughout the COVID-19 pandemic, anticoagulant drugs
such as unfractionated heparin (UFH) and low MW heparin (LMWH)
delivered systemically have been widely used across the world as part
of standard treatment for patients in intensive care units (ICU). The
use of these drugs has been shown to be effective for dealing with
coagulopathies seen during the late stage of the disease (Kollias
et al., 2020; Tang, Li, Wang, & Sun, 2020). Furthermore, heparin
exhibits a wide range of anti-inflammatory properties (Mulloy,
Hogwood, Gray, Lever, & Page, 2016), thus providing an additional
rationale for its clinical use to treat the hyperinflammatory response
observed in patients with COVID-19.
There is a recent and growing body of evidence suggesting that
UFH has antiviral properties against SARS-CoV-2, the causative agent
of COVID-19. UFH has been shown to bind to the receptor binding
domain (RBD) of the SARS-CoV-2 spike protein, which induces a con-
formational change (Mycroft-West et al., 2020) and also inhibits bind-
ing of spike protein to cells (Mycroft-West et al., 2020; Partridge,
Green, & Monk, 2020). Additional work with a pseudotyped assay
indicated that UFH has a half inhibitory maximal concentration (IC50)
of 0.6 μgml−1 (Tandon et al., 2020). Recent studies, performed with
live SARS-CoV-2 and Vero E6 cells, were limited to one heparin brand
(Celsus, USA) and showed SARS-CoV-2 virus was inhibited by 44–
80% with 6.25–200 μgml−1 of UFH in vitro (Mycroft-West, Su, Elli,
et al., 2020). Conzelmann et al. also report that heparin, sourced
from the company Sigma-Aldrich, suppressed viral replication of
SARS-CoV-2 in Vero E6 cells by 60% using 125–250 μgml−1 (Con-
zelmann et al., 2020) and most recently, Clausen et al. also show a
concentration-dependent inhibitory effect of UFH across the range of
1–100 μgml−1 in Vero E6 cells. They reported a fivefold reduction in
virus infection in primary human bronchial epithelial cells (Clausen
et al., 2020).
The accurate determination of the amount of heparin (μgml−1)
required to inhibit 50% of wild type, authentic, live SARS-CoV-2 virus
has yet to be reported in an in vitro system and a systematic assess-
ment of the antiviral activity of different commercially available hepa-
rins, already in clinical use, has yet to be performed. Once determined,
though, such an analysis should inform the selection of the most
appropriate heparin preparation having the most antiviral activity. The
determination of the IC50 of different heparin preparations will also
enable a quantitative comparison between different heparin sources,
for example bovine and porcine, and heparins with different MWs, for
example UF and LMWH. Such a systematic analysis should also
enable a quantitative comparison with other drugs under investigation
as treatments for COVID-19, for example remdesivir.
Independent from the systemic use of heparin in COVID-19
patients, nebulised heparin has been proposed as a unique and
potentially effective treatment for different stages of COVID-19
disease (van Haren et al., 2020). In the United Kingdom, a clinical
trial evaluating the effectiveness of nebulised UFH in hospitalised
COVID-19 patients is currently underway (https://accord-trial.org).
The strategy underpinning this treatment stems from positive
observations made, based on anticoagulant and anti-inflammatory
activity, when running trials of nebulised heparin in patients with
acute lung injury and other respiratory conditions (van Haren
et al., 2020). The delivery of an aerosolised antiviral agent directly
to the lungs where SARS-CoV-2 virus is known to be present
(both upper and lower respiratory tract) (Schaefer et al., 2020) may
help to treat the alveolar coagulopathy that is often a feature of
COVID-19, reduce the hyperinflammatory response and prevent
patients from developing acute respiratory distress syndrome
(ARDS) and pulmonary fibrosis (PF), the major complications of
infection with SARS-CoV-2.
Here, we report for the first time a systematic assessment of the
antiviral activity of a range of heparins (UFH and LMWH) in vitro
against live wild type SARS-CoV-2, thereby shedding light on the ant-
iviral potency of a range of different heparin preparations, including
the nebulised UFH already undergoing clinical trials in COVID-19
patients. We used a 24-well, 5-day plaque inhibition assay to assess
the antiviral activity of heparin, in a biosafety level 3 containment
laboratory. This classical, virological technique has been used
previously to assess the antiviral activity of compounds against other
viruses, for example influenza virus (Hayden, Cote, & Douglas, 1980).
We also report evidence for a direct mechanism of action via inhibi-
tion of binding of the spike protein receptor binding domain (RBD) on
the angiotensin-converting enzyme (ACE2).
2 | METHODS
2.1 | Heparin preparations
Clinically used LMWH preparations investigated were Innohep
(tinzaparin sodium, LEO Pharma), Clexane (enoxaparin sodium,
Sanofi), and Fragmin (dalteparin sodium, Pfizer), along with a porcine
mucosal UFH (heparin sodium, Wockhardt, UK) [currently being inves-
tigated by nebulisation in a UK human clinical trial]. Further heparin
preparations investigated were a porcine mucosal UFH preparation
(Celsus, USA) and both a bovine lung heparin (Calbiochem) and a
bovine mucosal heparin (15/110, NIBSC, UK).
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Specific anticoagulant activity for the UFH preparations was
measured as described in the United States Pharmacopeia (USP), n.d,
a general monograph for the assay of heparin. The MWs for the UFH
and LMWH samples were measured as previously described
(Mulloy & Hogwood, 2015). The specific activity of the clinical
LMWHs was taken from the clinical product information (Clexane,
100 IUmg−1; Innohep, 100 IUmg−1; Fragmin 130 IUmg−1).
2.2 | Plaque inhibition assay
SARS-CoV-2 (hCoV-19/Australia/VIC01/2020) (Caly et al., 2020) was
generously provided by The Doherty Institute, Melbourne, Australia,
at P1 and passaged twice in Vero/hSLAM cells [ECACC 04091501].
Whole genome sequencing was performed, on the working stock at
Passage 3, using both Nanopore and Illumina as described previously
(Lewandowski et al., 2019) and no significant changes in the viral
sequence were observed. Virus titre was determined by a plaque
assay on Vero E6 cells [ECACC 85020206]. Cell lines were obtained
from the European Collection of Authenticated Cell Cultures (ECACC)
PHE, Porton Down, UK. Cell cultures were maintained at 37C in
minimal essential media (MEM) (Life Technologies, California, USA)
supplemented with 10% FBS (Sigma, Dorset, UK) and 25 mM HEPES
(LifeTechnologies).
All heparin preparations were diluted, fivefold in MEM (Life
Technologies) containing 1% (v/v) FBS (Life Technologies), 1× antibi-
otic/antimycotic (Life Technologies) and 25 mM HEPES buffer (Sigma)
by diluting down in a 96-well plate. Dilutions were made fresh on the
day of the assay. SARS-CoV-2 was diluted to a concentration of
933 pfuml−1 (70 pfu/75 μl) in the same media and mixed 50:50 with
heparin dilutions, in a 96-well V-bottomed plate. The plate was
incubated at 37C in a humidified box for 1 h to allow the virus to be
exposed to heparin. The neutralised virus was transferred onto the
wells of a washed 24-well plate that had been seeded with Vero E6
cells the previous day at 1.5 × 105 cells per well. The virus/heparin
mixture was left to adsorb for an hour at 37C and then plaque assay
overlay media was applied (MEM containing 1.5% carboxymethylcel-
lulose [Sigma], 1× antibiotic/antimycotic [Life Technologies], 4% (v/v)
FBS and 25 mM HEPES buffer). After incubation at 37C in a humidi-
fied box, for 5 days, plates were fixed overnight with 20% (v/v) forma-
lin/PBS, washed with tap water and then stained with methyl crystal
violet solution (0.2% v/v) (Sigma),and plaques were counted. A series
of eight dilutions (fivefold) were prepared for each heparin prepara-
tion, in triplicate (technical replicates) to ensure that the most accu-
rate prediction of the IC50 could be obtained with the narrowest 95%
confidence interval. Repeat experiments (n = 5) were performed on
different days (independent experiments). Heparin dilutions with cells
only were also run in duplicate, to determine if there was any cell
cytotoxicity.
An internal positive control for the plaque inhibition assay was
run in duplicate using a sample of heat-inactivated human MERS con-
valescent serum known to neutralise SARS-CoV-2 (National Institute
for Biological Standards and Control [NIBSC], UK).
2.3 | Recombinant RBD-SD1 expression and
purification
Secreted Spike protein RBD-SD1 was transiently produced in suspen-
sion HEK293-6E cells. A plasmid encoding RBD-SD1, residues
319–591 of 2019-nCoV S were cloned upstream of a C-terminal
HRV3C protease cleavage site; a monomeric Fc tag and an His8x Tag
were a gift from Jason S. McLellan, University of Texas at Austin,
USA. Briefly, 100 ml of HEK293-6E cells were seeded at a cell density
of 0.5 × 106 cellsml−1 24 h before transfection with poly-
ethyleneimine (PEI). For transfection, 100 μg of the ACE2 plasmid and
300 μg of PEI (1:3 ratio) were incubated for 15 min at room tempera-
ture. Transfected cells were cultured for 48 h and fed with 100 ml
fresh media for additional 48 h before harvest. RBD-SD1 was purified
by HiTrap Protein G HP column (GE Healthcare, USA) pre-equilibrated
in PBS and eluted with 0.1 M glycine (pH 2.7). Purity of proteins was
evaluated by Coomassie staining of SDS-PAGE gels and proteins were
quantified by BCA Protein Assay Kit (Thermo Scientific).
2.4 | Differential scanning fluorimetry
Differential scanning fluorimetry (DSF) (Katarzna et al., 2010) was per-
formed employing the hydrophobic dye Sypro orange (1.25 X; Invi-
trogen) to monitor the thermal denaturation of RBD-SD1 (1 μg per
well) alone or in the presence of 200 μg heparin (Celsus or
Wockhardt) in PBS pH 7.6 with a total well volume of 40 μl. To ensure
that a change in melting temperature was not a result of interactions
between Sypro orange and heparin (Celsus or Wockhardt), control
wells containing H2O or heparin (Celsus or Wockhardt) without
mS1-RBD were also screened. Melt curve experiments were per-
formed in 96-well qPCR plates (AB Biosystems) using an AB bio-
systems StepOne plus qPCR machine with the TAMRA filter setting
enabled. An initial incubation of 2 min at 25C was set, increasing
sequentially by 0.5C increments every 30 s up to 90C. Melt curves
were smoothed (nine neighbours, second-order polynomial, Savitxky-
Golay) and first differential plots were constructed utilising Prism
8 (GraphPad). The peak of the first differential plots was used to cal-
culate Tm values using MatLab software (R20018a, MathWorks) and
the difference between mean values (n = 6 independent experiments)
was calculated using a Student's t-test in Prism 8 (GraphPad). Studies
on Wockhardt heparin were exploratory (n = 3 independent experi-
ments) due to limited availability of the RBD protein.
2.5 | ELISA assay for measuring inhibition of RBD-
ACE2 binding
Streptavidin (3 μgml−1; Fisher) in 50 mM sodium carbonate buffer
pH 9.6 (50 μl per well) was incubated for 1 h at 37C in high binding
96-well plates (Greiner). Plates were blocked with PBS, 0.2% Brij35
(w/v) + 1% casein (w/v) for 1 h at 37C, after washing thrice with
PBS, 0.2% Brij35 (w/v) (PBSB). Plates were washed again with PBSB
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and then incubated with biotinylated-ACE2 (Sino Biological) in
PBSB + 1% (w/v) casein for 1 h at 37C. mS1-RBD in PBSB + 1%
casein (w/v) was preincubated separately for 30 min at r.t. with or
without heparin at distinct concentrations (100–0.7 μgml−1), before
addition to the prewashed plates containing immobilised ACE2. Plates
were subsequently incubated for 1 h at 37C and washed with PBSB.
Bound mS1-RBD was detected by incubation with 0.5 μgml−1
Rabbit-SARS-CoV-2 (2019-nCoV) Spike RBD Antibody (Stratech) in
PBSB + 1% (w/v) casein (50 μl per well) for 1 h at 37C. Plates were
washed thrice with PBSB before being incubated for 30 min at 37C
with HRP-conjugated Donkey anti-Rabbit IgG, diluted 1:1000 (v/v) in
PBSB + 1% casein (w/v) (Biolegend). Plates were washed thoroughly
with PBSB before being developed with 3,30 ,5,50-
tetramethylbenzidine prepared according to the manufacturer's
instructions (Sigma). After 10 min colour development, the reaction
was stopped through the addition of 20 μl, 2 M HsSO4 and well-
absorbances were determined at λ = 450 nm using a Tecan Infinate
M200 Pro multiwell plate reader (Tecan Group). Control wells
containing no biotinylated ACE2 were employed to ensure binding
was specific. These ELISA studies were exploratory (n = 3 independent
experiments) due to limited availability of the key reagents (RBD,
biotinylated ACE2 and Spike antibody).
2.6 | Data and statistical analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018). A series of eight dilutions
(fivefold) were prepared for each heparin preparation, in triplicate
(technical replicates). Repeat plaque inhibition assays were run on
different days, at random, to ensure true independence and unbias
treatment. The samples were run in a partly blinded style as the
operator conducting the assays did not see the results. The repeat of
assays was limited to five occasions because these biological experi-
ments were lengthy (5 days) and run at biosafety level 3 containment.
Competing demands for the high containment facilities during the
current pandemic meant 1 heparin preparation (Fragmin LMWH) was
repeated only four times. A midpoint probit analysis (written in R pro-
gramming language for statistical computing and graphics) was used
to determine the amount of heparin (μgml−1) required to inhibit
SARS-CoV-2 viral plaques by 50% (IC50) compared with the virus only
control (n = 10). All outliers were included in the midpoint probit
analysis. The analysis was conducted in R (R Project, 2019) and the
script was based on a source script from Johnson, Dahlgren,
Siegfried, & Ellis, 2013 (Johnson et al., 2013). Data are presented as
geometric mean ± SEM (n = 5) and were tested for normality via
Shapiro–Wilk test. When a statistical comparison between two
groups was performed, a Welch's two-sample t-test was used in
R. This test was only performed when group sizes were n ≥ 5.
P < 0.05 value was considered statistically significant. The declared
group size is the number of independent values and the statistical
analysis was done using these independent values.
2.7 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY http://www.guidetopharmacology.org and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/1820
(Alexander et al., 2017).
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4,200 ± 250 100c 7,809 ± 2,237 2.7 5
aRounded to the nearest 50 Da, n = 2 independent measurements.
bThis is the same batch of Wockhardt heparin used to treat patients with COVID-19, UK.
cThese values are based on specific activities quoted by the manufacturers.
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3 | RESULTS
The characteristics of the different unfractionated heparins (UFHs)
and low MW heparins (LMWHs) are detailed in Table 1. A concentra-
tion-dependent relationship between the amount of heparin (μgml−1)
and the antiviral activity against SARS-CoV-2 was observed for all
heparin preparations tested. Increasing concentrations of heparin cau-
sed a reduction in the number of viral plaques compared to the con-
trol. Five independent plaque inhibition experiments were run for
each heparin preparation, unless otherwise stated. The geometric
mean IC50 and the pIC50 values for each heparin preparation are
stated in Table 1. Representative data (midpoint probit curve ± 95%
confidence intervals) from one independent plaque inhibition experi-
ment for each UFH is presented graphically in Figure 1a–d, a summary
of all the experimental data is presented in Table 1. Similarly, repre-
sentative data from one independent plaque inhibition experiment for
each LMWH preparation are presented in Figure 2a–c and a summary
is presented in Table 1. The midpoint probit plots show the spread of
data across different dose ranges.
3.1 | Unfractionated heparins (UFHs)
The antiviral activity of different UFHs fell within the range
of 25–41 μgml−1 (Table 1). The two porcine unfractionated
heparins obtained from Wockhardt (clinical batch) and Celsus had
geometric mean IC50 values of 41 and 31 μgml−1, respectively
(Table 1). There was no significant difference between the IC50
values for Celsus and Wockhardt heparin (Welch's two-sample
t-test, n = 5, P > 0.05). Similarly, there was no significant differ-
ence between the IC50 values for heparin sourced from bovine
lung (geometric mean IC50 25 μgml−1) or bovine mucosa
(geometric mean IC50 34 μgml−1) (Welch's two-sample t-test,
n = 5, P > 0.05) (Table 1). To determine if there was an effect of
species on the antiviral activity of UFHs, the bovine mucosa
and bovine lung data were grouped (n = 10) and the two porcine
UFHs were grouped (n = 10). When compared using a Welch's
t-test, there was no significant difference (P > 0.05) between the
species.
3.2 | Low MW heparins (LMWHs)
The LMW heparins Innohep and Clexane had an inhibitory
effect on the growth of SARS-CoV-2, with geometric mean IC50
values of 3.7 and 7.8 mgml−1, respectively. There was no
significant difference between the IC50 values for Clexane and
Innohep heparin preparations (Welch's two-sample t-test, n = 5,
P > 0.05) Mycroft-West et al. (2020). Exploratory experiments
were performed with the LMW heparin Fragmin, this clinical
preparation also had antiviral activity with an IC50 value of
3.4 mgml−1.
F IGURE 1 Unfractionated
heparins (UFHs) inhibit live wild
type SARS-CoV-2 infectivity in
Vero E6 cells. The % viral plaque
reduction, compared to virus only
control, caused by increasing
concentrations (μgml−1) of
different unfractionated heparins
in vitro with Vero E6 cells. Five
independent experiments were
run for Wockhardt UFH (n = 5),
Celsus UFH (n = 5), bovine lung
UFH (n = 5),and bovine mucosa
UFH (n = 5). Representative data
presented here graphically are
taken from one independent
experiment that had three
technical replicates and a
summary of all the data is
presented inTable 1. Midpoint
probit curves are plotted with
95% confidence intervals (dashed
lines): (a) Wockhardt UFH (clinical
batch), (b) Celsus UFH, (c) bovine
UFH (lung), (d) bovine UFH
(mucosa)
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3.3 | Comparison unfractionated heparins (UFHs)
and low MW heparins (LMWHs)
Overall, the antiviral activity of LMWH was 150-fold lower than
the activity of UFH (Table 1); thus, more LMW heparin (μgml−1)
was required to reduce the same amount of SARS-CoV-2 virus.
Since there was no significant difference between the antiviral
activity of Celsus and Wockhardt the data was grouped (n = 10).
Similarly, the data were grouped for the LMWHs Clexane and
Innohep (n = 10). When the grouped UFH and the grouped
LMWH data were compared using a Welch's two-sample t-test
there was a significant difference (P < 0.05) between the IC50
values of UFH and LMWH, indicating the antiviral activity of
porcine mucosa UFH is significantly greater than porcine
mucosa LMWH.
3.4 | Effect of molecular weight
The antiviral activity shown by the different heparins appeared to cor-
relate broadly with their MW. Overall, UFHs with the highest MWs
ranging between 15,650 and 19,100 Da were more potent inhibitors
of SARS-CoV-2 than low MW heparins ranging between 4,200 and
6,650 Da (Table 1).
3.5 | Mechanisms of action of heparin against
SARS-CoV-2—Destabilisation of spike protein RBD
and inhibition of RBD binding to human ACE2
Since previous work has indicated interactions of heparin with spike
protein RBD, we first confirmed a direct interaction of UF heparins
with soluble S1 RBD domain (RBD-SD1) expressed in HEK239 cells
by exploring their effects on protein thermal stability using differential
scanning fluorimetry (DSF). DSF exploits conventional real time PCR
machines to monitor the thermal denaturation of a protein through a
range of temperatures, in the presence of a hydrophobic fluorescent
dye. Upon heating, the hydrophobic regions of proteins become
exposed upon unfolding, resulting in increased fluorescence. The mid-
point of unfolding (Tm) can be determined through the first differential
of the resulting melt curve and changes in Tm values in the presence
of ligands can be used to determine binding affinity (Niesen,
Berglund, & Vedadi, 2007). This method has previously been exploited
to characterise the structural requirements of heparin for binding to
FGFs (Uniewicz et al., 2010). Celsus heparin with RBD-SD1 elicited a
significant reduction in the melting temperature (ΔTm) of 3.25C
(Figure 3a; P < 0.05, n = 6 independent experiments). Exploratory data
on Wockhardt heparin indicated that it induces a similar reduction in
Tm of 2.4C (Figure 3b). This confirmed a direct interaction of heparin
with RBD and furthermore suggests a significant destabilisation of the
F IGURE 2 Low MW heparins
(LMWHs) inhibit live wild type
SARS-CoV-2 infectivity in Vero
E6 cells. The % viral plaque
reduction, compared to the virus
only control, caused by increasing
concentrations (μgml−1) of
different LMWH preparations,
in vitro with Vero E6 cells. Five
independent experiments were
run for Clexane LMWH (n = 5)
and Innohep LMWH (n = 5); only
four independent experiments
were run for Fragmin LMWH
(n = 4), so these data are
preliminary. Representative data
presented graphically here are
taken from one independent
experiment that had three
technical replicates and a
summary of all the data is
presented inTable 1. Midpoint
probit curves are plotted with
95% confidence intervals (dashed
lines): (a) Innohep LMWH,
(b) Fragmin LMWH and
(c) Clexane LMWH
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RBD protein structure which could alter its ability to interact with the
ACE2 cell receptor.
In order to both validate the human relevance of our data and
also evaluate the potential mechanism by which heparin might inhibit
SARS-CoV-2 binding to human cells, we utilized an ELISA assay with
surface immobilised recombinant human ACE2 to measure the bind-
ing of RBD-SD1. Binding of RBD-SD1 to human ACE2 protein was
confirmed by detection with an anti-RBD antibody (Figure 4). In
exploratory experiments, a concentration response assay using Celsus
UFH demonstrated potent inhibition of binding, with an IC50
geometric mean of 16.2 ± 9.3 μgml−1 (n = 3 independent
experiments, ±SEM) (Figure 4). These data are in very close agreement
with the heparin inhibition data for live SARS-CoV-2 infectivity of
Vero E6 cells (Table 1). Notably, these data support the human
relevance of our data on the inhibition of SARS-CoV-2 infection of
Vero E6 cells by heparins and provides strong evidence for a direct
mechanism in which heparin destabilises the spike protein RBD and
inhibits its binding to the ACE2 cell receptor.
4 | DISCUSSION
Some studies have already reported the association between treat-
ment with systemically administered heparin and lower mortality in
patients admitted to hospital with COVID-19 (Ayerbe, Risco, &
Ayis, 2020; Tang et al., 2020), assumed to be a consequence of the
known anticoagulant effect. Coagulopathies have caused major
problems in late stage COVID-19 disease (Kollias et al., 2020) and the
use of heparin in the treatment of COVID-19 has become part of the
standard care for many patients in ICU. However, the dose and type
of heparin (UFH or LMWH) delivered either by the subcutaneous or
intravenous route varies across the world. Regarding standard sys-
temic usage, the therapeutic range for UFH is typically 0.3–0.7 IUml−1
(2–4 μgml−1) (Hirsh, Anand, Halperin, & Fuster, 2001), with peak
dosing concentrations reaching 10–20 μgml−1. It is reassuring to
see that the IC50 values for porcine UFH is 31–41 μgml−1, which is
close to the peak dosing range suggesting that at least partial antiviral
effects could be expected in this setting. It is also feasible that heparin
could be used in combination with alternative anti-viral agents acting
via different mechanisms, to gain therapeutic advantage.
F IGURE 3 Unfractionated heparins (UFs) interact directly with
spike protein RBD domain. Differential scanning fluorimetry was
employed to measure the thermal stability curve for recombinant
RBD in the absence of presence of UF heparin. First differential of
the thermal stability of 1 μg RBD alone (solid line) or with 200 μg UF
heparin (a, Celsus UF, dashed line; b, Wockhardt UF, dashed line).
(Figure 3a; P < 0.05, n = 6 independent experiments). *Significant
difference between the Tm value of RBD (46.4C ± 0.25 (±SD); n = 6
independent experiments) compared to RBD + Celsus UF
(43.1C ± 0.8; n = 6), t(10) = 8.854, P < 0.05. ΔTm = 3.25C. In
exploratory experiments (n = 3 independent experiments)
Wockhardt UF displayed a Tm value of 44.0C ± 0.6 (n = 3), indicating
a ΔTm of 2.4C
F IGURE 4 Unfractionated heparin (UF) hdirectly inhibits binding
of spike protein RBD to ACE2 protein receptor. Biotinylated ACE2
was captured onto a high binding microplate coated with streptavidin
prior to the addition of RBD preincubated with or without varying
concentrations of Celsus UF heparin. Detection of bound RBD was
achieved with an anti-RBD antibody. In exploratory studies (n = 3
independent experiments), the IC50 observed was 16.2 ± 9.3 μgml−1
(±SEM). Representative example shown (IC50, 24.6 μgml−1)
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In the United Kingdom, Brazil and Australia, in addition to
systemic heparin use, the novel approach of delivering UFH via
nebulisation directly to lungs of COVID-19 patients is undergoing
evaluation in a clinical trial by the ACCORD clinical trials platform
(https://accord-trial.org/) (van Haren et al., 2020). This is to determine
if there is a benefit from the additional known anti-inflammatory
activity of heparin and to provide high local anti-coagulant effects on
the alveolar region of patients with severe COVID-19. Nebulisation
allows for the targeting of lung tissue directly and therefore impact
upon the local hyperinflammatory response and alveolar coagulation
resulting from SARS-CoV-2 viral load in the lung. During the UK trial,
UFH (Wockhardt) will be administered at 25,000 IU (130 mg) every
6 h to patients. The efficiency of nebulising UFH through a high effi-
ciency mesh nebuliser is estimated to be about 20%; thus, the deliv-
ered dose to the lung is 26 mg. Assuming the normal human airway
surface fluids are in the range 10–60 ml (Frohlich, Mercuri, Wu, &
Salar-Behzadi, 2016), the peak amount of UFH delivered to the lung
should be 400–2,600 μgml−1, though these values could be lower if
diluted by increased fluid volumes as a result of pulmonary oedema.
Even allowing for this, these values greatly exceed the IC50 of
41 μgml−1 reported here for the same batch of Wockhardt UFH as
used in the current UK clinical trial. Thus, nebulisation of UFH should
provide strong antiviral effects, in vivo. Importantly, inhaled UFH does
not enter the systemic coagulation in any meaningful way so that
nebulised UFH can be used safely on top of standard of care involving
the systemic use of UFH or LMWH as an anticoagulant.
Previous work has demonstrated that LMWHs also bind to the
SARS-CoV-2 (Mycroft-West, Su, Li, et al., 2020). However, in the pre-
sent study, we observed that LMWHs were markedly less potent in
live SARS-CoV-2 virus assays (IC50 values of 3.4–7.8 mgml−1) than
UFH. Using the results reported here LMWH would appear unlikely
to reach sufficient concentration to achieve significant antiviral
activity for either systemic or nebulisation delivery. The typical thera-
peutic range for LMWH for anticoagulant therapy is 5–8 μgml−1
(0.6–1 IUml−1). Consistent with our data, the relationship (fold differ-
ence, 170-fold) between UFH and enoxaparin (Clexane) seen here
was close to that observed by Tandon et al. (2020) using a pseudo-
typed lentivirus inhibition assay where 180-fold difference was seen
(Tandon et al., 2020). In addition, LMWHs were also observed to be
less potent than UFH for inhibition of cell binding by spike protein
(Partridge et al., 2020). However, an important caveat is that the
potency of UFH and LMWHs remains to be determined in a suitable
range of human cells relevant to those affected in individuals infected
with SARS-CoV-2, perhaps especially from respiratory tract tissues.
The results of the present study also suggest a dependency on
MW for different UFH and LMWH preparations. A positive correla-
tion between MW and antiviral activity was noted for the various
porcine LMWHs (4,200–6,650 Da) and UFH preparations tested
which supports the hypothesis that UFH is more active due to its
higher MW (15,650–19,100 Da). Consistent with these live virus
data, MW dependency for binding of heparin and heparan sulfate
saccharides to spike protein has been observed (Liu et al., 2020;
Mycroft-West, Su, Pagani, et al., 2020). In terms of a molecular
explanation for this effect, data from molecular modelling have indi-
cated multiple binding sites on RBD for heparin, including some near
the RBD-ACE2 interface (Clausen et al., 2020; Mycroft-West, Su, Elli,
et al., 2020). Based on these data, we anticipate that longer heparin
chains may be able to bind more efficiently to multiple sites and also
potentially extend beyond RBD protein to interfere directly with the
ACE2 binding of the spike protein and this would be consistent with
our ELISA data demonstrating inhibition of RBD-ACE2 interaction by
heparin.
Recent work has demonstrated that cell surface heparan sulfate is
a necessary coreceptor with ACE2 that mediates SARS-CoV-2 virus
infection of cells (Bermejo-Jambrina et al., 2020; Clausen et al., 2020).
Regarding the underlying mechanisms, we provided additional
evidence here for the action of heparin to destabilise the RBD protein
structure (Figure 3) and notably the first evidence for the ability of
heparin to directly inhibit binding of the RBD to its protein receptor
human ACE2 (Figure 4). Both these pieces of data are supported by
recent preliminary observations using native MS (Yang, Du, &
Kaltashov, 2020). Thus, there is a clear mechanistic basis supporting
the notion of targeting these interactions with heparin and related
compounds. It is also notable that binding of RBD to human lung
cancer cell lines can be potently inhibited by heparin (Clausen
et al., 2020), strongly supporting the view that our data showing
inhibition of live SARS-CoV-2 infectivity of monkey Vero E6 cells, a
widely used experimental model, will also be relevant in vivo for
inhibiting infection of human cells.
In the present study, bovine UFH (IC50 25–34 μgml−1) had a
similar level of potency when compared to porcine UFH (IC50
31–41 μgml−1). The potent antiviral activity seen for both porcine
and bovine heparins suggests that this property is not species
dependent. Bovine UFH may provide an additional source of
heparin to use during the coronavirus pandemic. Currently,
therapeutic UFH available in Europe and United States is of
porcine mucosal origin. However, owing to supply issues there is
now interest, specifically in the United States, employing bovine
mucosal UFH as an additional source to improve the robustness
of supply chains (Hogwood, Mulloy, & Gray, 2017; Szajek
et al., 2015).
The antiviral (IC50) data for the different UFH and LMWHs dis-
play no obvious correlation with anticoagulant activities (IUmg−1),
indicating that different structure–activity relationships exist for
antiviral activity. Importantly, this suggests that further investigation
of non-anticoagulant heparins (Cassinelli, Torri, & Naggi, 2020;
Lindahl & Li, 2020) and heparin mimetics (Guimond et al., 2020;
Lindahl & Li, 2020) is warranted. Mimetics have significant potential
to target similar antiviral mechanisms and could be delivered
systemically at higher doses to improve efficacy without potential
side effects such as bleeding. This would apply to a broad range of
patients, not only those requiring anticoagulation. Moreover,
mimetics would also provide a fully synthetic route to bypass limita-
tions of heparin supply.
Here, we provide evidence for the first time that various types of
commercially available and clinically used UFH preparations exhibit
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potent antiviral efficacy against live wild type SARS-CoV-2 in vitro.
This activity was seen across different preparations of UFH and was
also observed with both porcine and bovine heparins and is supported
by data indicating a mechanism of action via inhibition of RBD binding
to human ACE2. These data indicate that current clinical use of
systemic UFH in the treatment of COVID-19 patients in an ICU
setting may provide useful antiviral benefits. Moreover, we predict
that the delivery of UFH to the lung (via nebulisation) should provide
a strong direct antiviral therapy in addition to other documented
beneficial effects of heparins.
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